The majority of breast cancer patients fall into the HR-positive/HER2-negative (HR+/HER2-) subtype. High-risk clinical and/or pathologic features increase the risk of recurrence, particularly in the initial years of adjuvant endocrine therapy. Patients who experience disease recurrence have poorer prognosis and overall outcomes. Preventing early recurrences and metastases is crucial, as more than 90% of breast cancer patients are diagnosed with early-stage disease. Community clinicians hold a predominant role in treating the majority of cancer patients. Early identification of high-risk patients is crucial to increase the likelihood of achieving disease control and improving long-term outcomes. Understanding and recognizing these factors allows for personalized treatment plans and improved outcomes for patients with early-stage breast cancer in the community setting.
Novel therapies offer potential for reducing the risk of distant relapse in patients with HR+/HER2- early breast cancer, improving overall outcomes. CDK4/6 inhibitors (CDK4/6i) represent a major breakthrough in the treatment of HR+/HER2- advanced breast cancer, leading to the exploration of CDK4/6i for the treatment of early-stage HR+/HER2- breast cancer. In addition, combining CDK4/6i with treatments that inhibit the downstream estrogen-dependent stimulation of cancer cells, such as endocrine therapy, has been shown to enhance the efficacy of treatment. To date, one CDK4/6 inhibitor is FDA-approved in combination with endocrine therapy for the adjuvant treatment of patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence, with others in development.
This educational activity will address the needs of community-based clinicians in the identification and management of HR+/HER2- early-stage breast cancer patients at high risk for recurrence. Expert thought leaders will not only present recent and emerging clinical data and challenging cases, but also offer expert insights and advice based on their own real-world clinical practice experiences regarding accelerating the adoption of CDK4/6 inhibitors into early breast cancer treatment. The activity will review adjuvant clinical trials and efficacy data to help clinicians assess and capitalize on the sustained benefits of treatment with CDK4/6i, as well as the management of treatment-related adverse events for CDK4/6i plus endocrine therapy to maximize adherence. The activity will empower community-based clinicians and ultimately enhance the quality of care provided to HR+/HER2- early breast cancer patients, leading to improved long-term treatment outcomes and patient well-being.
Community Practice Perspectives: Exploring Treatment Intensification with CDK 4/6 Inhibitors in Adjuvant HR+, HER2-, High-Risk Early Breast Cancer
Overview
Program Schedule*
- Introduction
- When, and in whom, is treatment intensification needed to prevent recurrence?
- Optimizing adjuvant therapy to sustain clinical benefit
- Implementation of evidence into treatment planning
- Engaging the patient to maximize adherence and persistence
- Practical Application Case-Based Learning Lab
- Activity Conclusion and Q&A
*Subject to Change
Disclosure of Conflicts of Interest
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:Reshma L. Mahtani, DO, reported a financial interest/relationship or affiliation in the form of Consultant: Agendia, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Eisai Inc., Genentech, Inc., Gilead, Hologic, Lilly, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Sanofi, SeaGen & Stemline.
Research grant, Gilead.
The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP, hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.Learning Objectives
After participating in this educational activity, participants should be better able to:
- Utilize consensus-based guidelines to identify patients at high risk of recurrence
- Apply guidelines and evidence for CDK4/6 inhibitors in combination with ET to reduce recurrence in patients with high-risk HR+/HER2- early breast cancer
- Develop team-based mitigation and management strategies for CDK 4/6 inhibitor-related and ET-related adverse events to reduce toxicities and treatment discontinuation
- Employ collaborative team-based communication strategies to foster patient engagement, adherence, and persistence of therapy
Target Audience
This educational activity is designed for community-based medical oncologists, breast oncologists, and advanced practice nurses, physician assistants, and pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 12/31/2024. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-019-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com.
There is no fee for this educational activity.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
The majority of breast cancer patients fall into the HR-positive/HER2-negative (HR+/HER2-) subtype. High-risk clinical and/or pathologic features increase the risk of recurrence, particularly in the initial years of adjuvant endocrine therapy. Patients who experience disease recurrence have poorer prognosis and overall outcomes. Preventing early recurrences and metastases is crucial, as more than 90% of breast cancer patients are diagnosed with early-stage disease. Community clinicians hold a predominant role in treating the majority of cancer patients. Early identification of high-risk patients is crucial to increase the likelihood of achieving disease control and improving long-term outcomes. Understanding and recognizing these factors allows for personalized treatment plans and improved outcomes for patients with early-stage breast cancer in the community setting.
Novel therapies offer potential for reducing the risk of distant relapse in patients with HR+/HER2- early breast cancer, improving overall outcomes. CDK4/6 inhibitors (CDK4/6i) represent a major breakthrough in the treatment of HR+/HER2- advanced breast cancer, leading to the exploration of CDK4/6i for the treatment of early-stage HR+/HER2- breast cancer. In addition, combining CDK4/6i with treatments that inhibit the downstream estrogen-dependent stimulation of cancer cells, such as endocrine therapy, has been shown to enhance the efficacy of treatment. To date, one CDK4/6 inhibitor is FDA-approved in combination with endocrine therapy for the adjuvant treatment of patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence, with others in development.
This educational activity will address the needs of community-based clinicians in the identification and management of HR+/HER2- early-stage breast cancer patients at high risk for recurrence. Expert thought leaders will not only present recent and emerging clinical data and challenging cases, but also offer expert insights and advice based on their own real-world clinical practice experiences regarding accelerating the adoption of CDK4/6 inhibitors into early breast cancer treatment. The activity will review adjuvant clinical trials and efficacy data to help clinicians assess and capitalize on the sustained benefits of treatment with CDK4/6i, as well as the management of treatment-related adverse events for CDK4/6i plus endocrine therapy to maximize adherence. The activity will empower community-based clinicians and ultimately enhance the quality of care provided to HR+/HER2- early breast cancer patients, leading to improved long-term treatment outcomes and patient well-being.Program Schedule*
- Introduction
- When, and in whom, is treatment intensification needed to prevent recurrence?
- Optimizing adjuvant therapy to sustain clinical benefit
- Implementation of evidence into treatment planning
- Engaging the patient to maximize adherence and persistence
- Practical Application Case-Based Learning Lab
- Activity Conclusion and Q&A
*Subject to Change
Disclosure of Conflicts of Interest
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:Reshma L. Mahtani, DO, reported a financial interest/relationship or affiliation in the form of Consultant: Agendia, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Eisai Inc., Genentech, Inc., Gilead, Hologic, Lilly, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Sanofi, SeaGen & Stemline.
Research grant, Gilead.
The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP, hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.Learning Objectives
After participating in this educational activity, participants should be better able to:
- Utilize consensus-based guidelines to identify patients at high risk of recurrence
- Apply guidelines and evidence for CDK4/6 inhibitors in combination with ET to reduce recurrence in patients with high-risk HR+/HER2- early breast cancer
- Develop team-based mitigation and management strategies for CDK 4/6 inhibitor-related and ET-related adverse events to reduce toxicities and treatment discontinuation
- Employ collaborative team-based communication strategies to foster patient engagement, adherence, and persistence of therapy
Target Audience
This educational activity is designed for community-based medical oncologists, breast oncologists, and advanced practice nurses, physician assistants, and pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 12/31/2024. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-019-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com.
There is no fee for this educational activity.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?